Overexpression of miR-101 suppresses collagen synthesis by targeting EZH2 in hypertrophic scar fibroblasts

Abstract

Background: MicroRNA-101 (miR-101) is a tumor suppressor microRNA (miRNA) and its loss is associated with the occurrence and progression of various diseases. However, the biological function and target of miR-101 in the pathogenesis of hypertrophic scars (HS) remains unknown. Methods: We harvested HS and paired normal skin (NS) tissue samples from patients and cultured their fibroblasts (HSF and NSF, respectively). We used quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), fluorescence in situ hybridization (FISH), enzyme-linked immunosorbent assays (ELISA) and Western blot analyses to measure mRNA levels and protein expression of miR-101, enhancer of zeste homolog 2 (EZH2), collagen 1 and 3 (Col1 and Col3) and α-smooth muscle actin (α-SMA) in different in vitro conditions. We also used RNA sequencing to evaluate the relevant signaling pathways and bioinformatics analysis and dual-luciferase reporter assays to predict miR-101 targets. We utilized a bleomycin-induced fibrosis mouse model in which we injected miR-101 mimics to evaluate collagen deposition in vivo. Results: We found low expression of miR-101 in HS and HSF compared to NS and NSF. Overexpressing miR-101 decreased Col1, Col3 and α-SMA expression in HSF. We detected high expression of EZH2 in HS and HSF. Knockdown of EZH2 decreased Col1, Col3 and α-SMA in HSF. Mechanistically, miR-101 targeted the 3′-untranslated region (3′UTR) of EZH2, as indicated by the decreased expression of EZH2. Overexpressing EZH2 rescued miR-101-induced collagen repression. MiR-101 mimics effectively suppressed collagen deposition in the bleomycin-induced fibrosis mouse model. Conclusions: Our data reveal that miR-101 targets EZH2 in HS collagen production, providing new insight into the pathological mechanisms underlying HS formation.

Keywords

Hypertrophic scars / miR-101 / EZH2 / Collagen / Fibroblasts / Skin / Collagen

References

[1] Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet. 2016; 388: 1427-36.

[2] Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020; 8: tkz003. https://doi.org/10.1093/burnst/tkz003.

[3] Zhu H, Li J, Li Y, Zheng Z, Guan H, Wang H, et al. Glucocorticoid counteracts cellular mechanoresponses by LINC01569-dependent glucocorticoid receptor-mediated mRNA decay. Sci Adv. 2021; 7: eabd9923.

[4] Kim HJ, Cantor H, Cosmopoulos K. Overcoming immune checkpoint blockade resistance via EZH2 inhibition. Trends Immunol. 2020; 41: 948-63.

[5] Li Z, Wang D, Lu J, Huang B, Wang Y, Dong M, et al. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020; 27: 3226-42.

[6] Lu W, Liu S, Li B, Xie Y, Izban MG, Ballard BR, et al. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Oncogene. 2017; 36: 1364-73.

[7] Zhang X, Schulz R, Edmunds S, Kruger E, Markert E, Gaedcke J, et al. MicroRNA-101 suppresses tumor cell proliferation by acting as an endogenous proteasome inhibitor via targeting the proteasome assembly factor POMP. Mol Cell. 2015; 59: 243-57.

[8] Liu JJ, Lin XJ, Yang XJ, Zhou L, He S, Zhuang SM, et al. A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res. 2014; 42: 12041-51.

[9] Cui G, Wang H, Liu W, Xing J, Song W, Zeng Z, et al. Glycogen phosphorylase B is regulated by miR101-3p and promotes hepatocellular carcinoma tumorigenesis. Front Cell Dev Biol. 2020; 8: 566494. https://doi.org/10.3389/fcell.2020.566494.

[10] Li Z, Qu Z, Wang Y, Qin M, Zhang H. miR-101-3p sensitizes non-small cell lung cancer cells to irradiation. Open Med (Wars). 2020; 15: 413-23.

[11] Zhu HY, Li C, Bai WD, Su LL, Liu JQ, Li Y, et al. MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts. PLoS One. 2014; 9: e97114. https://doi.org/10.1371/journal.pone.0097114.

[12] Udhaya Kumar S, Thirumal Kumar D, Bithia R, Sankar S, Magesh R, Sidenna M, et al. Analysis of differentially expressed genes and molecular pathways in familial hypercholesterolemia involved in atherosclerosis: a systematic and bioinformatics approach. Front Genet. 2020; 11: 734. https://doi.org/10.3389/fgene.2020.00734.

[13] Yao Q, Wu Q, Xu X, Xing Y, Liang J, Lin Q, et al. Resveratrol ameliorates systemic sclerosis via suppression of fibrosis and inflammation through activation of SIRT1/mTOR signaling. Drug Des Devel Ther. 2020; 14: 5337-48.

[14] Liang X, Chai B, Duan R, Zhou Y, Huang X, Li Q, et al. Inhibition of FKBP10 attenuates hypertrophic scarring through suppressing fibroblast activity and extracellular matrix deposition. J Invest Dermatol. 2017; 137: 2326-35.

[15] Cameron AM, Adams DH, Greenwood JE, Anderson PJ, Cowin AJ. A novel murine model of hypertrophic scarring using subcutaneous infusion of bleomycin. Plast Reconstr Surg. 2014; 133: 69-78.

[16] Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017; 16: 151-5.

[17] Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013; 229: 298-309.

[18] Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010; 123: 4195-200.

[19] Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci. 2019; 20: 6249.

[20] Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018; 141: 1202-7.

[21] Zhang S, Wang M, Li Q, Zhu P. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR. Cancer Biomark. 2017; 21: 179-86.

[22] Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010; 42: 363-9.

[23] Zhang K, Dong C, Chen M, Yang T, Wang X, Gao Y, et al. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics. 2020; 10: 411-25.

[24] Bao J, Xu Y, Wang Q, Zhang J, Li Z, Li D, et al. miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother. 2017; 92: 1030-7.

[25] Cao K, Li J, Zhao Y, Wang Q, Zeng Q, He S, et al. miR-101 inhibiting cell proliferation, migration and invasion in hepatocellular carcinoma through downregulating girdin. Mol Cells. 2016; 39: 96-102.

[26] Dai L, Zhang X, Hu X, Zhou C, Ao Y. Silencing of microRNA-101 prevents IL-1β-induced extracellular matrix degradation in chondrocytes. Arthritis Res Ther. 2012; 14: R268.

[27] Ezhilarasan D. MicroRNA interplay between hepatic stellate cell quiescence and activation. Eur J Pharmacol. 2020; 885: 173507. https://doi.org/10.1016/j.ejphar.2020.173507.

[28] Tu X, Zhang H, Zhang J, Zhao S, Zheng X, Zhang Z, et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signaling pathway. J Pathol. 2014; 234: 46-59.

[29] Zhao JY, Wang XL, Yang YC, Zhang B, Wu YB. Upregulated miR-101 inhibits acute kidney injury-chronic kidney disease transition by regulating epithelial-mesenchymal transition. Hum Exp Toxicol. 2020; 39: 1628-38.

[30] Lei Y, Wang QL, Shen L, Tao YY, Liu CH. MicroRNA-101 suppresses liver fibrosis by downregulating PI3K/Akt/mTOR signaling pathway. Clin Res Hepatol Gastroenterol. 2019; 43: 575-84.

[31] Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 2012; 126: 840-50.

[32] Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020; 13: 104.

[33] Jiang Y, Xiang C, Zhong F, Zhang Y, Wang L, Zhao Y, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics. 2021; 11: 361-78.

[34] Xu L, Gao J, Huang D, Lin P, Yao D, Yang F, et al. Emodin ameliorates tubulointerstitial fibrosis in obstructed kidneys by inhibiting EZH2. Biochem Biophys Res Commun. 2021; 534: 279-85.

[35] Lim HJ, Kim M. EZH2 as a potential target for NAFLD therapy. Int J Mol Sci. 2020; 21: 8617-27.

[36] Shi Y, Tao M, Wang Y, Zang X, Ma X, Qiu A, et al. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis. J Pathol. 2020; 250: 79-94.